In RA patients, the use of anti-TNF drugs may increase the risk of NSCLC, a phenomenon that may be explained by the complex biological functions of TNF, the complexity of pharmacological intervention, and the differences between natural regulation and pharmacological intervention. Here, TNF is linked to non-small cell lung carcinoma.